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Background & objectives: Tbe interleukin (IL)-17 producing T-belper ceUs bave been linked to
patbogenesis of autoimmunity and mostly investigated in rbeumatoid artbritis (RA). In tbis study we
tested tbe IL-17 levels, as well as tbe levels of nitric oxide (NO) as possible IL-17-induced product, in
patients witb primary Sjögren's syndrome (pSS), an intricate and complex cbronic autoimmune disorder
of exocrine glands.
Methods: Serum IL-17 levels and nitrite concentrations determined in patients witb pSS (n=30) were
compared witb tbe values obtained in patients witb RA (n=10) and bealtby controls (n=15). Tbe values
obtained for IL-17 in pSS patients were also associated witb tbe patients' clinical cbaracteristics,
particularly tbe rbeumatoid factor (RF) and total antinuclear antibodies (tANA) levels.
Resuits: Serum concentrations of IL-17 were significantly (P<0.01) bigber in patients witb pSS (12.9 ±
28.0 pg/ml) as compared to tbose obtained in bealtby individuals (0.2 ± 0.6 pg/ml), but not as bigb as tbe
values obtained for tbe patients witb RA (34.5 ± 56.2 pg/ml). Tbe mean IL-17 levels were significantly
(P<0.05) bigber in tbe pSS patients positive for rbeumatoid factor (20.3 ± 33.3 pg/ml) tban in RF-negatives
(0.3 ± 0.6 pg/ml). Mean serum concentrations of IL-17 were also higber in antinuclear antibody (ANA)-
positive samples (19.8 ± 33.5 pg/ml) in comparison to ANA-negative sera (1.1 ± 3.1 pg/ml) (P<0.05).
Tbe NO levels also sbowed elevated values in botb pSS and RA patients, as compared to tbe bealtby
controls, since mean nitrite levels in patients witb pSS and RA were 38.2 ± 29.2 nM and 41.7 ± 21.1 fiM,
respectively, wbile tbose in bealtby controls were significantly lower, at 19.2 ± 10.5 jiM.
Interpretation & conciusions: Tbe findings of tbis study sbowed tbat tbere was increased IL-17 and NO
production in patients witb primary SS, especially if tbey bad associated elevated rbeumatoid factor and
antinuclear antibody values.
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Interleukin-17 (IL-17) and its receptor are members regulation of granulopoiesis and erythropoiesis-l Also,
of emerging cytokine family involved in pathogenesis newly recognized subset of IL-17-secreting T (Thl7)
of inflammation and host defense', as IL-17 exhibits cells has been identified and linked to pathogenesis
proinflammatory activity and appears to have a role in of autoimmunit/. The significance of IL-17 was
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mostly investigated in the pathology of rheumatoid
arthritis and other T cell dependent tissue damages^
A hallmark feature of IL-17 is its ability to induce the
production of a number of inflammatory mediators
and in particular nitric oxide (NO) by stimulated
chondrocytes, osteoblasts, fibroblast, endothelial cells
and astrocytes^ NO itself is well known free radical
implicated in cytotoxic tissue injury in a variety of
diseases and its increased production has been linked
to pathogenesis of autoimmune and inflammatory
Sjögren's syndrome (SS) is a chronic autoimmune
disorder of exocrine glands characterized as an
autoimmune exocrinopathy, and there are limited
reports concerning the levels, as well as the role, of
both IL-17 and NO in the in pathogenesis of primary
Sjögren's syndrome. Increased NO production has been
previously reported in patients with SS, especially ifthey
had associated arthritis^ Recently, the possible role of
systemic and local IL-17 was associated with primary
Sjögren's syndrome (pSS)'°. Cytokines as important
component in pathogenesis are considered as potential
targets in pSS" ' l Due to complex pathogenesis of pSS,
heterogeneity of disease and for determination of new
potential therapeutic targets the role of IL-17 should be
further elucidated". In order to gain more data on the
presence and the influence of IL-17 in the pathology
of pSS, we investigated the levels of IL-17 and NO in
patients with pSS and compared the values with those
obtained in patients with rheumatoid arthritis (RA)
and in healthy controls. Additionally, the IL-17 levels
in the pSS patients were associated with their clinical
characteristics, particularly the rheumatoid factors
(RF) and total antinuclear antibodies (tANA) levels.
Material & Methods
Patients: The study was conducted at the Institute
of Rheumatology, Belgrade, Serbia, and 40 patients
[30 with primary Sjögren's syndrome (pSS) and 10
with rheumatoid arthritis (RA)] were included with
a written consent, during one year period (January
to December 2004). The diagnosis of pSS was made
according to the European classification criteria'''
since the average duration of disease of patients was
10 years. The clinical samples were formed in a such
manner that each patient who met the entry criteria of
the study during the research period was included in the
corresponding group. Randomization of the samples
was a result of indeterminable patients reporting to the
clinic. All patients were women, mean age 55.2 ±10.1
yr with the mean duration of the disease 10.6 ± 5.6 yr.
The patients with pSS were on substitution therapy for
dry eyes and mouth, four of them only on substitution,
25 were treated with glycocorticoids, in addition, 11
of them with chloroquine, five with azathioprine, one
with cyclophosphamide. Seven patients with RA were
treated with nonsteroid anti inflammatory drugs and
monotherapy with disease modifing anti-rheumatic
drug (Methotrexate, Salazopyrine, Hloroquine,
Azathioprine), and three were on low doses of
prednisolone (5-7.5 mg/day). The blood samples ( 10 ml)
were drawn from patients and serum was separated and
investigated by routine clinical analyses for the presence
of rheumatoid factor (RF) by the nephelometric test
(The Binding site, Birmingham, UK), total antinuclear
antibodies (tANA) by an indirect immunofluorescent
test'^ and antibodies against SS-A and SS-B by
ELISA test (Varelisa, Pharmaciadiagnostics, Freiburg,
Germany). Extraglandular manifestations occurred in
all pSS patients studied.
RA patients fulfilling the revised criteria of the
American College of Rheumatology were included"".
The mean age of RA patients (all women) was 60 ±
13.8 yr and the mean duration of the disease 8.4 ±
7.7 yr; 80 per cent of RA patients had extra-articular
manifestations.
Fifteen healthy volunteers (13 female and 2
male), after written consent obtained, were studied as
controls and their mean age was 49 ± 11.1 yr. Blood
samples were drawn at the Institute of Rheumatology,
Belgrade. Serum was separated immediately and stored
at -20°C until analysis. The study was approved by
the Committee of Ethics, Institute of Rheumatology,
Belgrade.
Enzyme linked immunosorbent assay (ELISA) for
human IL-17: Serum IL-17 levels were determined in
duplicate by ELISA kit for human IL-17 (sensitivity-2
pg/ml) purchased from BioSource Europe S.A.
(BioSource IL-17 cytoscreen kit, Belgium), following
manufacturer's instruction.
Nitric oxide determination: Production of NO was
determined by measuring accumulation of nitrite in
serum using the Griess reaction with sodium nitrate
as the standard. Briefly, 50 ¡iL samples of serum were
mixed with equal volumes of 1 per cent sulphanil-
amide and 0,1 per cent N-1-naphthylethylene diamine-
dihydrochloride in 0.5 per cent H3PO4. After 10 min
at room temperature, the absorbance at 540 nm was
measured in a microplate reader.
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Statistical analyses: Descriptive statistical methods
were used. Data were not normally distributed, as
tested by one-sample Kolmogorov-Smimov test (KSZ).
Therefore, non-parametric tests were used, Kruskal-
Wallis chi-squared (KW x^ ) for differences between
three groups, and Mann-Whitney test (U) for inter-
group differences. P<0.05 was considered significant.
Results
The clinical and laboratory characteristics of the
patients with pSS and RA are shown in the Table. The
most common extraglandular manifestations in patients
with pSS were dermal changes (70%), Raynaud's
phenomenon (63.3%), sensitive neuropathy (53.3%),
arthralgia and arthritis (50%), and haematological
manifestations (40%). In these patients RF and ANA
were present in 19 (around 63%) patients, while anti-
SS-A and anti-SS-B in 18 (60%) and 12 (40%) patients,
respectively. In two patients with RA, rheumatic
nodules as extra-articular manifestations were found.
Serum IL-17 levels were significantly elevated
in patients with pSS as compared to the healthy
individuals (12.9 ± 28.0 vs. 0.2 ± 0.6 pg/ml, P<0.01).
Patients with RA also had significantly elevated serum
levels of IL-17 when compared to the controls (34.5 ±
56.2 vs. 0.2 ± 0.6 pg/ml, F<0.001) (Fig. lA). Though
the mean serum IL-17 levels were higher in patients
with RA than in the patients with pSS, the difference
was not statistically significant.
The NO levels levels in patients with pSS and
RA were significantly higher than those in healthy
(A)
Table. Clinical and laboratory characteristics of patients with
primary Sjögren's syndrome (pSS) and rheumatoid arthritis
(RA)
Parameter pSS
(n=30)
RA
Leucocytes (x 10') 5.6 ± 1.8
Hemoglobin (g/1) 119 ± 1.4
Thrombocytes (x 10') 223.3 ± 76.9
Erythrocyte sedimentation rate 31.3 ± 19.1
(mm/h)
Extraglandular manifestations 30 (100)
Extra-articular manifestations
RF positive
ANA positive
Anti-SS-A positive
Anti-SS-B positive
7.3 ±2.4
10.1 ±1.3
294.8 ±98.1
66 ±25.9
2(20)
9(90)
5(50)
19 (63.3)
19(63.3)
18(60.0)
12 (40.0)
Values are expressed as mean ± SD, values in parentheses are the
percentages; RF, rheumatoid factor; ANA, antinuclear antibody;
anti-SS-A (Ro) antibodies, anti-SS-B (La) antibodies
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Fig. 1. IL-17 (A) and nitrite (B) serum concentrations in patients
with pSS (n=30), patients with RA (n=10) and healthy controls - C
(n=15). Squares (red) represent mean values, the median is shown
as horizontal line within the box. The lower and upper margins
of the box represent 25* and 75"* percentiles, with the extended
arms representing the highest and lowest values. Differences in
serum levels between patients' groups and the control group were
analyzed by Mann-Whitney U test.
individuals (Fig. IB). Mean nitrite concentrations
in patients with pSS were 38.2 ± 29.2 ^M, while
those in healthy controls were significantly lower,
at 19.2 ± 10.5 t^M (P<0.05). In patients with RA,
mean NO levels were 41.7 ± 21.1 \xM, which was
also significantly higher in comparison to the control
group (P<0.001).
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Fig. 2. IL-17 concentration in serum of the patients with pSS
(n=30). The IL-17 levels were associated with (A) the disease
duration, (B) between the RF-negative and RF-positive patients,
and (C) between the tANA-negative and tANA-positives. Squares
represent mean values, the median is shown as horizontal line
within the box. The lower and upper margins of the box represent
25* and 75'" percentiles, with the extended arms representing the
highest and lowest values. Differences in IL-17 levels between the
tested groups were analyzed by Mann-Whitney U test CP<0.05).
The possible associated between the elevated
IL-17 levels in pSS patients was studied with their
clinical characteristics, especially the duration of the
disease and the presence of rheumatoid factors (RF)
and total antinuclear antibodies (tANA) levels. The
mean serum IL-17 concentrations were higher in
patients with pSS disease duration lasting longer than
10 years when compared to those with disease duration
< 10 yr. The difference was not statistically significant.
The results also demonstrated significantly higher IL-
17 concentrations in RF-positive than in RF-negative
patients (P<0.05) (Fig. 2B), as well as in ANA-positive
in comparison to ANA-negative patients (P<0.05)
(Fig. 2C).
No differences in the mean concentrations of IL-17
were found between the anti-SS-A positive and anti-
SS-Anegative patients (13.6 ± 18.7 vs. 15.4 ± 44.9 pg/
ml), nor between the anti-SS-B positive and anti-SS-B
negatives (13.6 ± 18.5 vs. 12.5 ± 33.4 pg/ml). Although
no relation between presence of anti-SS-A, anti-SS-B
antibodies and elevated IL-17 concentrations was found,
the values of anti-SS-A antibodies in patients (n=ll)
with elevated IL-17 concentration were considerably
higher than in those with normal (n=19) IL-17 values
(72.3 ± 54.7 vs. 37.7 ± 37.5 U/ml, P<0.05).
Discussion
This study demonstrated elevated IL-17 and NO
levels in the circulation of the patients with pSS,
which is in agreement with reported data"*-'"•''''I
The elevated IL-17 levels in pSS patients are most
probably a reflection of the systemic response to
the inflammation, like often seen in autoimmune
diseases. Proinflammatory effects of IL-17 were
clearly demonstrated in various autoimmune
diseases. Stimulation of its production and the
release of inflammatory mediators from synovial
fluid monocytes, synoviocytes and peripheral blood
mononuclear cells^'', as well as the additive and
synergistic effects with interleukin-1 (IL-1 ) and tumour
necrosis factor (TNF) in inducing joint pathology have
been described in rheumatoid arthritis^". Similarly, the
role of IL-17 as a crucial proinflammatory mediator
was demonstrated in the pathogenesis of other
autoimmune diseases, including multiple sclerosis^',
systemic lupus erythematosus^^ and autoimmune
encephalomyelitis^l IL-17 was, therefore, shown to
be incorporated in cytokine network acting in tissue
damage^ "*. In patients with pSS, systemic levels
of Thl7-associated cytokines, including IL-17,
significantly varied between different subgroups of
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patients as related to the histopathological features^l
Other studies showed the presence of IL-17 and
other factors fostering Thl7 lineage polarization,
such as IL-23, TGF-ß, IL-6, in the local salivary
gland milieu'"'^ that correlated with the degree of
inflammation and objective clinical evidence. These
data pointed towards the important role of IL-17 in
the immunopathogenesis of pSS and indentified this
cytokine as a potential therapeutic target. In a mouse
model of pSS, blood levels of IL-17 were detected at
early time points of the disease and were decreasing
further, indicating that early induction of a CD4+
Thl/Thl7 pathway leads to systemic release of IL-
17". However, based on the current knowledge, the
question of when Thl7 cells become involved in the
autoimmune response and whether these act directly
through secretion of inflammatory IL-17 family
cytokines or by activating autoimmune T and B cells
remains still to be defined. In our study, IL-17 was
detected in the one third of our patients with pSS, and
showed tendency to be higher in those patients with
long disease duration (more than 10 yr), implying that
the blood levels of this cytokine might be associated
with natural progression ofthe SS disease. Doreau et
af' have shown that IL-17 can infiuence the survival
and proliferation of B cells, and their differentiation
into immunoglobulin-secreting cells. It has been
assumed that the activation of B cells is an important
event in the pathogenesis of the disease". The
presence of autoantibodies in the circulation is one of
the evidence supporting B-cell activation in pSS, and
presence of RF and ANA in the serum of more than 60
per cent of our patients is in line with this assumption.
As in these pSS patients, either RF-positive or ANA-
positive, the average level of IL-17 was increased, a
role of IL-17 in maintenance of disease activity could
be supposed. Therefore, the consideration of the
disease heterogeneity might be important for finding
the most adequate therapeutic strategy.
In addition to IL-17, the results of this study
revealed increased NO levels in the circulation of pSS
patients, thus confirming that NO may contribute to
inflammatory damage in pSS'. Several studies have
established that the proinflammatory action of IL-17
depends considerably on its ability to induce inducible
NOS (iNOS) and stimulates significant NO production
in various cell types, including chondrocytes, astrocytes,
fibroblasts and endothelial cells'*. The possible role
of NO in the pathogenesis of different systemic
autoimmune disorders has also been indicated, since
elevated NO levels have been shown in pSS, SLE and
The fimctional outcome of the increased
NO production in patients with pSS, as well as
the mechanisms by which NO contributes to
pathophysiology, are still not resolved. Recent data
presented a role of the NO-mediated nitrosylation in
downregulation of salivary fiinction in a mouse model
for SS^°. However, other possible mechanisms of NO
action are not excluded; such is its effect in triggering
apoptosis, since in low concentrations NO may protect
cells fi-om apoptosis^', but at high concentrations,
resulting from the activation of iNOS, NO can induce
apoptosis^l As concerning SS apoptosis of the acinar
and ductal epithelial cells of the salivary and lacrimal
glands has been suggested as a possible mechanism
responsible for the impairment of secretory fianction".
In addition, in S S patients increased apoptosis and
increased iNOS expression were detected in salivary
epithelial cells, after the exposure to infiammatory
cytokines, such as INF-gamma^''.
In our study, there was no relation between the NO
production and the other clinical characteristics, such as
the disease duration, rheumatoid factors or antinuclear
antibody positivity, as well as with the elevated IL-17
concentrations (data not shown). However, one cannot
assert the objectivity of such findings, bearing in mind
that the majority of patients were under appropriate
therapy and that steroids are known to suppress NO
production'^ As the NO is also known to be implicated
in the enhancement of Thl cell proliferation and
function^^ it will be of great interest for future work to
investigate the impact of NO on the development and
fimction of Thl7 effector's T cells.
In summary, the present data demonstrated
increased IL-17 and NO production in patients with
primary SS. The elevated IL-17 levels were associated
with elevated rheumatoid factors and antinuclear
antibody values, confirming that IL-17 is an important
cytokine linked to the immunopathogenesis in
patients with pSS. But, since SS is a very intricate and
complex chronic autoimmune disease, further studies
are needed to determine the exact role of both IL-17
and NO, as well as their mutual link, in pSS disease
pathogenesis.
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